KEGG PATHWAY: map04936

PATHWAY: map04936 Help Entry map04936 Pathway Name Alcoholic liver disease Description Alcoholic liver disease (ALD) refers to the damages to the liver and its functions due to alcohol overconsumption. It ranges from simple steatosis to steatohepatitis, cirrhosis, and even hepatocellular carcinoma. Alcohol consumption promotes liver inflammation by increasing the translocation of gut-derived endotoxins to the portal circulation and activating Kupffer cells to produce TNF-alpha through the LPS/Toll like receptor (TLR) 4 pathways. TNF-alpha induces hepatocellular damage. When alcohol intake is chronic and heavy, steatosis is caused via generation of acetaldehyde, reactive oxygen species (ROS) and ER stress. ROS inhibits key hepatic transcriptional regulators such as AMP-activated kinase (AMPK) and peroxisome proliferator-activated receptor alpha (PPAR-alpha), which are responsible for fatty acid oxidation and export via ACC a

KEGG PATHWAY: map04936 PATHWAY: map04936 Help Entry map04936 Pathway Name Alcoholic liver disease Description Alcoholic liver disease (ALD) refers to the damages to the liver and its functions due to alcohol overconsumption. It ranges from simple steatosis to steatohepatitis, cirrhosis, and even hepatocellular carcinoma. Alcohol consumption promotes liver inflammation by increasing the translocation of gut-derived endotoxins to the portal circulation and activating Kupffer cells to produce TNF-alpha through the LPS/Toll like receptor (TLR) 4 pathways. TNF-alpha induces hepatocellular damage.

related reading

• Fructose: It’s “Alcohol Without the Buzz” - PMCncbi.nlm.nih.gov
• Hepatic Cirrhosis - StatPearls - NCBI Bookshelfncbi.nlm.nih.gov
• UpToDateuptodate.com
• UpToDateuptodate.com
• Nintil - The Longevity FAQnintil.com
• Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease - PMCpmc.ncbi.nlm.nih.gov
• EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease | Diabetologia | Springer Nature Linklink.springer.com
• Longevity FAQ - Laura Demingldeming.com
• ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? - PubMedpubmed.ncbi.nlm.nih.gov
• Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease | Current Atherosclerosis Reports | Springer Nature Linklink.springer.com
• Egg consumption and risk of non-alcoholic fatty liver disease - PMCpmc.ncbi.nlm.nih.gov
• Approach to the Patient with Liver Disease: A Guide to Commonly Used Liver Tests | Basicmedical Keybasicmedicalkey.com